(Q38073197)

28 August 2017

1 reference

title

Prolonged infusions of β-lactam antibiotics: implication for antimicrobial stewardship (English)

1 reference

28 August 2017

0 references

Jomy M George

1

1 reference

28 August 2017

Trent G Towne

series ordinal

2

1 reference

28 August 2017

Keith A Rodvold

series ordinal

3

1 reference

28 August 2017

language of work or name

English

0 references

publication date

1 August 2012

1 reference

28 August 2017

1 reference

28 August 2017

32

1 reference

28 August 2017

8

1 reference

28 August 2017

707-721

1 reference

Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship

28 August 2017

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01157.X

Pharmacodynamic modeling of intravenous antibiotics against gram-negative bacteria collected in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01157.X

Probability of pharmacodynamic target attainment with standard and prolonged-infusion antibiotic regimens for empiric therapy in adults with hospital-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01157.X

Pharmacodynamics of empirical antibiotic monotherapies for an intensive care unit (ICU) population based on Canadian surveillance data

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01157.X

Pharmacodynamic profiling of intravenous antibiotics against prevalent Gram-negative organisms across the globe: the PASSPORT Program-Asia-Pacific Region

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01157.X

Use of pharmacokinetic-pharmacodynamic target attainment analyses to support phase 2 and 3 dosing strategies for doripenem

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01157.X

Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01157.X

Comparative pharmacodynamics of intermittent and prolonged infusions of piperacillin/tazobactam using Monte Carlo simulations and steady-state pharmacokinetic data from hospitalized patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01157.X

Optimal dosing of piperacillin-tazobactam for the treatment of Pseudomonas aeruginosa infections: prolonged or continuous infusion?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01157.X

Outcomes of extended infusion piperacillin/tazobactam for documented Gram-negative infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01157.X

The Retrospective Cohort of Extended-Infusion Piperacillin-Tazobactam (RECEIPT) study: a multicenter study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01157.X

Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01157.X

Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01157.X

Pharmacodynamic optimization of beta-lactams in the patient care setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01157.X

Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin-tazobactam: implications on the appropriateness of the resistance breakpoint

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01157.X

Failure of current cefepime breakpoints to predict clinical outcomes of bacteremia caused by gram-negative organisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01157.X

Comparison of 30-min and 3-h infusion regimens for imipenem/cilastatin and for meropenem evaluated by Monte Carlo simulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01157.X

Population pharmacokinetics of doripenem based on data from phase 1 studies with healthy volunteers and phase 2 and 3 studies with critically ill patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01157.X

Pharmacokinetics and pharmacodynamics of cefepime administered by intermittent and continuous infusion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01157.X

Pharmacokinetics, safety, and tolerability of doripenem after 0.5-, 1-, and 4-hour infusions in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01157.X

Integration of population pharmacokinetics, a pharmacodynamic target, and microbiologic surveillance data to generate a rational empiric dosing strategy for cefepime against Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01157.X

Pharmacodynamic profiling of piperacillin in the presence of tazobactam in patients through the use of population pharmacokinetic models and Monte Carlo simulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01157.X

Pharmacodynamic assessment of doripenem in peritoneal fluid against Gram-negative organisms: use of population pharmacokinetic modeling and Monte Carlo simulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01157.X

The pharmacokinetics and pharmacodynamics of meropenem in the cerebrospinal fluid of neurosurgical patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01157.X

Steady-state plasma and intrapulmonary concentrations of cefepime administered in continuous infusion in critically ill patients with severe nosocomial pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01157.X

Penetration of meropenem into epithelial lining fluid of patients with ventilator-associated pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01157.X

Comparison of 2002-2006 OPTAMA programs for US hospitals: focus on gram-negative resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01157.X

Identification of optimal renal dosage adjustments for traditional and extended-infusion piperacillin-tazobactam dosing regimens in hospitalized patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01157.X

Population pharmacokinetics of high-dose, prolonged-infusion cefepime in adult critically ill patients with ventilator-associated pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01157.X

Pharmacodynamic-based clinical pathway for empiric antibiotic choice in patients with ventilator-associated pneumonia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01157.X

Comparison of the pharmacodynamics of meropenem in patients with ventilator-associated pneumonia following administration by 3-hour infusion or bolus injection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01157.X

Comparison of the pharmacodynamics of imipenem in patients with ventilator-associated pneumonia following administration by 2 or 0.5 h infusion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01157.X

Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01157.X

Pharmacokinetic-pharmacodynamic target attainment analysis of doripenem in infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01157.X

Pharmacokinetic-pharmacodynamic-model-guided doripenem dosing in critically ill patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01157.X

Pharmacokinetic-pharmacodynamic modeling to support doripenem dose regimen optimization for critically ill patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01157.X

Comparative stability studies of antipseudomonal beta-lactams for potential administration through portable elastomeric pumps (home therapy for cystic fibrosis patients) and motor-operated syringes (intensive care units)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01157.X

Pharmacokinetics of imipenem in healthy volunteers following administration by 2 h or 0.5 h infusion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01157.X

Implementation of an extended-infusion piperacillin-tazobactam program at an urban teaching hospital

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01157.X

Length of stay and hospital costs associated with a pharmacodynamic-based clinical pathway for empiric antibiotic choice for ventilator-associated pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01157.X

Experience with extended-infusion meropenem in the management of ventilator-associated pneumonia due to multidrug-resistant Acinetobacter baumannii

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01157.X

Hospital resource utilization with doripenem versus imipenem in the treatment of ventilator-associated pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01157.X

Medical resource utilization among patients with ventilator-associated pneumonia: pooled analysis of randomized studies of doripenem versus comparators

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01157.X

Cost-effectiveness model of empiric doripenem compared with imipenem-cilastatin in ventilator-associated pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01157.X

Economic evaluation of doripenem for the treatment of nosocomial pneumonia in the US: discrete event simulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01157.X

Stability of doripenem in vitro in representative infusion solutions and infusion bags

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01157.X

Stability of doripenem in polyvinyl chloride bags and elastomeric pumps

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01157.X

Compatibility of doripenem with other drugs during simulated Y-site administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01157.X

Stability and compatibility study of cefepime in comparison with ceftazidime for potential administration by continuous infusion under conditions pertinent to ambulatory treatment of cystic fibrosis patients and to administration in intensive care u

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.2012.01157.X

10.1002/J.1875-9114.2012.01157.X

21 January 2018

Identifiers

DOI

1 reference

28 August 2017

1 reference